The purpose of this study is to determine the safety and effectiveness of Azixa in patients with recurrent glioblastoma multiforme

Inclusion Criteria:

• Have histologically proven malignant Glioblastoma Multiforme in first or second relapse
• Have failed prior Fractionated External Beam Cranial Irradiation or IMRT
• Be at least 18 years old and with a life expectancy ≥ 8 weeks or ≥ 4 weeks if failed prior Avastin therapy
• Have a Karnofsky performance status of ≥ 60
• Have adequate bone marrow function, liver function, and renal function before starting therapy

Exclusion Criteria:

• Have had more than two relapses
• Have had radiosurgery
• Have a cardiac ejection fraction < 50% by MUGA or ECHO
• Have Troponin-I elevated above the normal range
• Have an increasing steroid requirement
• Have MRI evidence at baseline of enlarging or clinically significant intratumor hemorrhage
• Have active stroke and/or transient ischemic attack not optimally managed
• Have active cardiovascular disease (e.g. sub-optimally managed angina, impending myocardial infarction, or uncontrolled hypertension)
• Be pregnant or breast feeding
• Have had prior hypersensitivity reaction to Cremophor EL
• Be HIV positive